Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Oramed Pharmaceuticals (ORMP) Divestments (2025)

Oramed Pharmaceuticals filings provide 3 years of Divestments readings, the most recent being $2.8 million for Q3 2025.

Quarterly Divestments changed N/A to $2.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.3 million for FY2025, N/A changed from the prior year.
Divestments hit $2.8 million in Q3 2025 for Oramed Pharmaceuticals, up from $43208.0 in the prior quarter.
Across five years, Divestments topped out at $2.8 million in Q3 2025 and bottomed at $2.8 million in Q3 2025.